|
Nitta Kosaku
Department Other, Other Position |
|
| Article types | Original article |
| Language | English |
| Peer review | Non peer reviewed |
| Title | Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study. |
| Journal | Formal name：Journal of nephrology Abbreviation：J Nephrol ISSN code：17246059/11218428 |
| Volume, Issue, Page | 35(4),pp.1135-1144 |
| Author and coauthor | Yamamoto Ryohei, Imai Enyu, Maruyama Shoichi, Yokoyama Hitoshi, Sugiyama Hitoshi, Takeda Asami, Tsukamoto Tatsuo, Uchida Shunya, Tsuruya Kazuhiko, Shoji Tatsuya, Hayashi Hiroki, Akai Yasuhiro, Fukunaga Megumu, Konta Tsuneo, Nishio Saori, Goto Shunsuke, Tamai Hirofumi, Nagai Kojiro, Katafuchi Ritsuko, Masutani Kosuke, Wada Takashi, Nishino Tomoya, Shirasaki Arimasa, Sobajima Hiroshi, Nitta Kosaku, Yamagata Kunihiro, Kazama Junichiro J, Hiromura Keiju, Yasuda Hideo, Mizutani Makoto, Akahori Toshiyuki, Naruse Tomohiko, Hiramatsu Takeyuki, Morozumi Kunio, Mimura Tetsushi, Saka Yosuke, Ishimura Eiji, Hasegawa Hajime, Ichikawa Daisuke, Shigematsu Takashi, Sato Hiroshi, Narita Ichiei, Isaka Yoshitaka, |
| Publication date | 2022/05 |
| Summary | BACKGROUND:Minimal change disease (MCD) is characterized by a nephrotic syndrome usually steroid-sensitive and a high incidence of relapse of proteinuria. Previous cohort studies have reported conflicting results regarding the association between the time to remission and incidence of relapse.METHODS:This multicenter prospective cohort study included 102 adult patients with steroid-sensitive MCD or focal segmental glomerulosclerosis from a 5-year cohort study of primary nephrotic syndrome, the Japan Nephrotic Syndrome Cohort Study, who achieved remission of proteinuria within 2 months of immunosuppressive therapy (IST). The association between the time to remission of proteinuria after immunosuppressive therapy and incidence of relapse was assessed using Cox proportional hazards models adjusted for clinically relevant factors.RESULTS:Remission was observed at 3-7, 8-14, 15-21, 22-28, and 30-56 days after initiation of immunosuppressive therapy in 17 (16.7%), 37 (36.3%), 21 (20.6%), 13 (12.7%), and 14 (13.7%) patients, respectively. During a median observation period of 2.3 years after the end of the 2nd month after initiation of immunosuppressive therapy, 46 (45.1%) patients relapsed. The time to remission was associated with the incidence of relapse in an inverse U-shaped pattern (multivariable-adjusted hazard ratios [95% confidence intervals] of the time to remission of 3-7, 8-14, 15-21, 22-28, 30-56 days: 1.00 [reference], 1.76 [0.56, 5.51], 6.06 [1.85, 19.80], 5.46 [1.44, 20.64], and 2.19 [0.52, 9.30], respectively).CONCLUSION:The time to remission was identified as a significant predictor of relapse in steroid-sensitive patients. |
| DOI | 10.1007/s40620-022-01279-z |
| PMID | 35366214 |